Advance notification letters increase adherence in colorectal cancer screening: A population-based randomized trial

Preventive Medicine

Volumn 52, Issue 6, 2011, Pages 448-451

  Van Roon, A H C ^a   Hol, L ^a   Wilschut, J A ^a   Reijerink, J C I Y ^b   van Vuuren, A J ^a   van Ballegooijen, M ^a   Habbema, J D F ^a   van Leerdam, M E ^a   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Association of Nationwide Screening for the Southwestern Netherlands   (Netherlands)

Author keywords

Adherence; Advance notification letter; Colorectal cancer screening; Population based; Randomized trial

Indexed keywords

ADULT; ADVANCE NOTIFICATION LETTER; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POPULATION RESEARCH; POSTAL MAIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMINDER SYSTEM; WRITTEN LANGUAGE;

AGED; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PATIENT ACCEPTANCE OF HEALTH CARE; REMINDER SYSTEMS;

EID: 79957882830     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2011.01.032     Document Type: Article

References (18)

1. American Cancer Society Cancer Facts & Figures 2010 2010, American Cancer Society, Atlanta.
2. Bastos J., Peleteiro B., Gouveia J., Coleman M., Lunet N. The state of the art of cancer control in 30 European countries in 2008 2009, Int J Cancer.
3. Cole S.R., Smith A., Wilson C., Turnbull D., Esterman A., Young G.P. An advance notification letter increases participation in colorectal cancer screening. J. Med. Screen. 2007, 14:73-75.
4. Compton C.C., Greene F.L. The staging of colorectal cancer: 2004 and beyond. CA Cancer J. Clin. 2004, 54:295-308.
5. Hardcastle J.D., Armitage N.C., Chamberlain J., Amar S.S., James P.D., Balfour T.W. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer 1986, 58:397-403.
6. Hewitson P., Glasziou P., Irwig L., Towler B., Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007, CD001216-CD.
7. Hoffman R.M., Steel S., Yee E.F., Massie L., Schrader R.M., Murata G.H. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev. Med. 2010, 50:297-299.
8. Hol L., Van Leerdam M.E., Van Ballegooijen M., Van Vuuren A.J., Van Dekken H., Reijerink J.C., Van Der Togt A.C., Habbema J.D., Kuipers E.J. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010, 59:62-68.
9. Hol L., Wilschut J.A., Van Ballegooijen M., Van Vuuren A.J., Van Der Valk H., Reijerink J.C., Van Der Togt A.C., Kuipers E.J., Habbema J.D., Van Leerdam M.E. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br. J. Cancer 2009, 100:1103-1110.
10. Keighley M.R., O'Morain C., Giacosa A., Ashorn M., Burroughs A., Crespi M., Delvaux M., Faivre J., Hagenmuller F., Lamy V., Manger F., Mills H.T., Neumann C., Nowak A., Pehrsson A., Smits S., Spencer K., United European Gastroenterology Federation Public Affairs Public awareness of risk factors and screening for colorectal cancer in Europe. Eur. J. Cancer Prev. 2004, 13:257-262.
11. King J., Fairbrother G., Thompson C., Morris D.L. Colorectal cancer screening: optimal compliance with postal faecal occult blood test. Aust. N. Z. J. Surg. 1992, 62:714-719.
12. Lieberman D.A. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995, 109:1781-1790.
13. Meissner H.I., Breen N., Klabunde C.N., Vernon S.W. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol. Biomarkers Prev. 2006, 15:389-394.
14. Myers R.E., Ross E.A., Wolf T.A., Balshem A., Jepson C., Millner L. Behavioral interventions to increase adherence in colorectal cancer screening. Med. Care 1991, 29:1039-1050.
15. O'Connell J.B., Maggard M.A., Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 2004, 96:1420-1425.
16. Power E., Miles A., Von Wagner C., Robb K., Wardle J. Uptake of colorectal cancer screening: system, provider and individual factors and strategies to improve participation. Future Oncol 2009, 5:1371-1388.
17. Van Roon A.H., Wilschut J., Van Leerdam M.E., Van Ballegooijen M., Van Vuuren A.J., Francke J., Reijerink J.C., Habbema J.D., Kuipers E.J. Costs of guaiac versus immunochemical fecal occult blood testing within a randomized population-based colorectal cancer screening trial. Gastroenterology 2010, 138:S-189-S-190.
18. Zajac I.T., Whibley A.H., Cole S.R., Byrne D., Guy J., Morcom J., Young G.P. Endorsement by the primary care practitioner consistently improves participation in screening for colorectal cancer: a longitudinal analysis. J. Med. Screen. 2010, 17:19-24.